CFMS Conformis

Prestigious Klee Family Foundation Prize 2020 Awarded for Outstanding Scientific Work Identifying Patient-Specific Approach as Better Way to Optimize Knee Implant Design

Prestigious Klee Family Foundation Prize 2020 Awarded for Outstanding Scientific Work Identifying Patient-Specific Approach as Better Way to Optimize Knee Implant Design

Dr. Malte Asseln awarded annual prize by German Society for Biomedical Engineering at the VDE Association and the Klee Family Foundation for his scientific computer-and-image-based workflow to optimize knee implant design

BILLERICA, Mass., May 21, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) congratulates Dr. Malte Asseln for winning the prestigious Klee Prize 2020 for his dissertation and computer-and-image-based workflow on the optimization of knee implant design - “Morphological and Functional Analysis of the Knee Joint for Implant Design Optimization.”   

As reported in on May 6, 2020, Dr. Asseln’s results show that more knee implant sizes are required than are currently manufactured by off-the-shelf knee implant manufacturers, so patient-specific or better-tailored solutions are a promising approach to increase the 70 percent industry-wide patient satisfaction with artificial knee joints that he has observed.

Dr. Asseln concluded that one of the main drivers of the 30 percent industry-wide dissatisfaction with knee implants is the design of standard implants, which takes insufficient account of patient-specific biomechanics.

“I am always pleased to see third-party scientific research validate my belief in the inherent superiority of the patient-specific knee implant design approach over standard, off-the-shelf knee design to eliminate joint pain relief,” said Mark Augusti, President and CEO of Conformis, Inc. “Congratulations to Dr. Asseln!”

As part of his analysis, Dr. Asseln developed methods for generating parameterized surface models of articular surfaces to enable systematic shape variations. He also developed a patient-specific biomechanical simulation model of the lower extremity and an experimental bench test to analyze the relationship between design parameters and knee function. Further, he used the outer geometric dimensions of the knee joint to calculate a sufficient number of implant sizes.

For his morphological analysis of the natural knee joint, Dr. Asseln built up a comprehensive database with geometric features and evaluated them. He used a database of 831 patient records, from which 59 geometric features were extracted.

Most traits showed statistically significant gender differences. After Dr. Asseln classified and normalized the features according to the direction of their measurement (i.e. width and depth), it became apparent that, after normalization, there were large inter-individual deviations, which indicates that patient-specific design solutions would be the only way to accommodate for these differences.

About The Klee Prize and the VDE Association

The Klee Prize is an annual prize awarded by the German Society for Biomedical Engineering at the VDE Association and the Klee Family Foundation. The prize is worth 5,000 euros and is awarded in a competition for outstanding scientific work in biomedical engineering as an interdisciplinary subject.

With 36,000 members (including 1,300 companies) the VDE Association for Electrical, Electronic & Information Technologies is one of the largest technical and scientific associations in Europe. VDE works in the fields of information technology, energy, medical engineering, microelectronics, micro and nanotechnology and automation. VDE is headquartered in Frankfurt am Main, Germany, and has main branches in Brussels, Belgium and Berlin, Germany.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy.  Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals.  In clinical studies, the Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants.  Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit .  To receive future releases in e-mail alerts, sign up at ir.conformis.com.

CONTACT:
Investor Contact
  
+1 (781) 374-5598
EN
21/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Conformis

 PRESS RELEASE

restor3d Completes Acquisition of Conformis

restor3d Completes Acquisition of Conformis Combination Creates the World’s Preeminent Producer of Personalized Orthopedic Medical Devices, with Unmatched Additive Manufacturing Capabilities DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis’ stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis’ common stock ceased tr...

 PRESS RELEASE

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conform...

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote “FOR” the Pending Merger with restor3d BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co., LLC (“Glass Lewis”), have each recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d. As previously announced, und...

 PRESS RELEASE

Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders ...

Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote “FOR” the Pending Merger with restor3d BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will a...

 PRESS RELEASE

Conformis Reports Second Quarter 2023 Financial Results

Conformis Reports Second Quarter 2023 Financial Results BILLERICA, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Summary Total revenue of $13.0 million, a decrease of 15% year-over-year on a reported and constant currency basis.Product revenue of $12.5 million, a decrease of 17% year-over-year on a reported and constant currency basis.Conformis hip system revenue ...

 PRESS RELEASE

Conformis Announces Definitive Agreement to be Acquired by restor3d fo...

Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash Combination creates a leading personalized 3D-printed orthopedic medical device company DURHAM, N.C. and BILLERICA, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. (NASDAQ: CFMS) announced today that they have entered into a definitive merger agreement under which restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approxi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch